[The use of misoprostol in prevention of gastric disease from nonsteroidal anti-inflammatory drugs in oral-maxillofacial surgery].
The results of a clinical experiment with a new synthetic prostaglandin for the prevention of gastric lesions induced by NSAID: the misoprostol have reported. Twenty patients were treated with this drug and the results were compared to those obtained with the use of ranitidine in the same number of patients. The clinical experiment showed an excellent misoprostol-induced gastric protection which compared to ranitidine presents the advantage of a multiple and pathogenetically oriented action mechanism.